Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Cash from Investing Activities: 2015-2024

Historic Cash from Investing Activities for Axsome Therapeutics (AXSM) over the last 10 years, with Dec 2024 value amounting to -$270,000.

  • Axsome Therapeutics' Cash from Investing Activities rose 35.56% to -$58,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$439,000, marking a year-over-year decrease of 77.73%. This contributed to the annual value of -$270,000 for FY2024, which is 53.61% up from last year.
  • Per Axsome Therapeutics' latest filing, its Cash from Investing Activities stood at -$270,000 for FY2024, which was up 53.61% from -$582,000 recorded in FY2023.
  • In the past 5 years, Axsome Therapeutics' Cash from Investing Activities registered a high of -$45,891 during FY2020, and its lowest value of -$53.7 million during FY2022.
  • Its 3-year average for Cash from Investing Activities is -$18.2 million, with a median of -$582,000 in 2023.
  • Its Cash from Investing Activities has fluctuated over the past 5 years, first slumped by 17,335.71% in 2022, then surged by 98.92% in 2023.
  • Yearly analysis of 5 years shows Axsome Therapeutics' Cash from Investing Activities stood at -$45,891 in 2020, then tumbled by 571.16% to -$308,000 in 2021, then crashed by 17,335.71% to -$53.7 million in 2022, then skyrocketed by 98.92% to -$582,000 in 2023, then spiked by 53.61% to -$270,000 in 2024.